SCHEMBL2477879

SCHEMBL2477879

Cc1ccc(F)cc1-c1ccccc1C=O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
TSHR P16473 1/20 0.47
FLT3 P36888 3/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.40
BLM P54132 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KCNN4 O15554 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
ERN1 O75460 1/20 0.38
KDM4E B2RXH2 1/20 0.38
PDE2A O00408 1/20 0.38
PDE10A Q9Y233 1/20 0.38
NISCH Q9Y2I1 1/20 0.37
NFE2L2 Q16236 2/20 0.37
PGR P06401 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6862609 0.86 ALDH1A1 (0.47) ALDH1A1TSHRFLT3MEN1KMT2A
SCHEMBL3679520 0.82 MEN1 (0.46) ALDH1A1TSHRMEN1KMT2ALMNA
SCHEMBL2471502 0.79 ALDH1A1 (0.47) ALDH1A1TSHRMEN1KMT2ALMNA
SCHEMBL10304929 0.79 CYP1A2 (0.45) ALDH1A1TSHRFLT3MEN1KMT2A
SCHEMBL1765158 0.79 TSHR (0.67) ALDH1A1TSHRMEN1KMT2ALMNA
SCHEMBL19154298 0.79 NFE2L2 (0.47) ALDH1A1FLT3MEN1KMT2ALMNA
SCHEMBL31322080 0.78 FLT3 (0.40) ALDH1A1FLT3MEN1KMT2ALMNA
SCHEMBL9139591 0.77 NISCH (0.52) LMNAPDE2APDE10ANISCH
SCHEMBL30377758 0.77 NISCH (0.52) LMNAPDE2APDE10ANISCH
SCHEMBL15803551 0.76 ALDH1A1 (0.42) ALDH1A1TSHRFLT3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2159216-B1 3-BUTENYL-1-AMINE DERIVATIVES AND THEIR USE AS Ih MODULORS FOR THE TREATMENT OF PSYCHIATIRC DISORDERS ORGANON NV (NL) 2011-10-12 EP disclosed
EP-2159216-A1 Ih - Modulators N.V. Organon (NL) 2010-03-03 EP disclosed
US-20040229910-A1 Therapeutic compounds N.V. ORGANON (NL) 2004-11-18 US disclosed
US-20020037885-A1 Therapeutic compounds DIJCKS FREDERICUS ANTONIUS (NL) 2002-03-28 US disclosed
US-6313139-B1 ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS AKZO NOBEL N. V. (NL) 2001-11-06 US disclosed
EP-1035843-A2 I h?-MODULATORS Akzo Nobel N.V. (NL) 2000-09-20 EP disclosed
US-6080773-A USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS AKZO NOBEL, N.V. (NL) 2000-06-27 US disclosed
WO-1999018941-A2 Ih-MODULATORS AKZO NOBEL N.V. (NL) 1999-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229910-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 ALDH1A1 964/4885TSHR 2499/4885FLT3 3029/4885
US-20020037885-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 ALDH1A1 964/4885TSHR 2499/4885FLT3 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.